Lamond David bought QNCX
January 2, 2026 · Form 4 insider transaction
Lamond David bought 29,423 shares of Quince Therapeutics, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 19 days after the transaction.
Direction
Acquired (buy-side)
Shares
29,423
Price
$0.00
Total value
N/A
InsiderLamond David
RoleDirector
SecurityDirector Stock Option (Right to Buy)
Transaction codeA: Grant or award
Transaction dateJanuary 2, 2026
Filing dateJanuary 21, 2026
Shares owned after29,423
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2026 provided for under the Issuer's Outside Director Compensation Policy.